Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Gain Therapeutics, Inc. - Common Stock (NQ:GANX)

1.810 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 26, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,409
Open	1.810
Bid (Size)	1.830 (900)
Ask (Size)	1.850 (500)
Prev. Close	1.810
Today's Range	1.810 - 1.810
52wk Range	1.530 - 4.340
Shares Outstanding	27,132,588
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference

August 25, 2026

From Gain Therapeutics, Inc.

Via GlobeNewswire

Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update

August 11, 2026

From Gain Therapeutics, Inc.

Via GlobeNewswire

Performance

YTD	-43.1%	-43.1%
1 Month	-2.7%	-2.7%
3 Month	+2.3%	+2.3%
6 Month	-28.2%	-28.2%
1 Year	-5.7%	-5.7%

More News

Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update

July 16, 2026

From Gain Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

June 29, 2026

Via Benzinga

Wondering what's happening in today's after-hours session? ↗

June 29, 2026

Via Chartmill

Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease

June 29, 2026

From Gain Therapeutics, Inc.

Via GlobeNewswire

Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit

June 10, 2026

From Gain Therapeutics, Inc.

Via GlobeNewswire

Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026

May 26, 2026

From Gain Therapeutics, Inc.

Via GlobeNewswire

Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update

May 11, 2026

From Gain Therapeutics, Inc.

Via GlobeNewswire

Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026

April 24, 2026

From Gain Therapeutics, Inc.

Via GlobeNewswire

Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update

March 26, 2026

From Gain Therapeutics, Inc.

Via GlobeNewswire

Gain Therapeutics to Present at the 38th Annual ROTH Conference

March 19, 2026

From Gain Therapeutics, Inc.

Via GlobeNewswire

Which stocks are moving on Wednesday? ↗

March 18, 2026

Via Chartmill

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

March 18, 2026

Via Chartmill

Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026

March 18, 2026

From Gain Therapeutics, Inc.

Via GlobeNewswire

Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update

March 12, 2026

From Gain Therapeutics, Inc.

Via GlobeNewswire

Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 19, 2026

From Gain Therapeutics, Inc.

Via GlobeNewswire

Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week

January 07, 2026

From Gain Therapeutics, Inc.

Via GlobeNewswire

Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287

January 06, 2026

From Gain Therapeutics, Inc.

Via GlobeNewswire

Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease

December 18, 2025

From Gain Therapeutics, Inc.

Via GlobeNewswire

Keep an eye on the top gainers and losers in Thursday's session. ↗

December 18, 2025

Via Chartmill

There are notable gap-ups and gap-downs in today's session. ↗

December 18, 2025

Via Chartmill

Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease

December 18, 2025

From Gain Therapeutics, Inc.

Via GlobeNewswire

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025

November 20, 2025

From Gain Therapeutics, Inc.

Via GlobeNewswire

Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update

November 12, 2025

From Gain Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Gain Therapeutics, Inc. - Common Stock publicly traded?

Yes, Gain Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Gain Therapeutics, Inc. - Common Stock trade on?

Gain Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Gain Therapeutics, Inc. - Common Stock?

The ticker symbol for Gain Therapeutics, Inc. - Common Stock is GANX on the Nasdaq Stock Market

What is the current price of Gain Therapeutics, Inc. - Common Stock?

The current price of Gain Therapeutics, Inc. - Common Stock is 1.810

When was Gain Therapeutics, Inc. - Common Stock last traded?

The last trade of Gain Therapeutics, Inc. - Common Stock was at 08/26/26 04:00 PM ET

What is the market capitalization of Gain Therapeutics, Inc. - Common Stock?

The market capitalization of Gain Therapeutics, Inc. - Common Stock is 49.11M

How many shares of Gain Therapeutics, Inc. - Common Stock are outstanding?

Gain Therapeutics, Inc. - Common Stock has 49M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.